Stock Events

Stock Events

Neovacs 

€0.4300
27
-€0.02-3.59% Friday 06:05

Statistics

Day High
0.43
Day Low
0.43
52W High
5,410
52W Low
0.43
Volume
-
Avg. Volume
-
Mkt Cap
16.1M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-11,812.38%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
541,000Revenue
-63.91MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0LW1.MU. It's not an investment recommendation.
TotalEnergies
5
TTE.PA
Lvmh Moet Hennessy Louis Vuitton
4
MC.PA
NVIDIA
3
NVDA
Bitcoin
3
BTC.CRYPTO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the development of novel immunotherapies, similar to Neovacs' focus on therapeutic vaccines for autoimmune diseases.
Moderna
MRNA
Mkt Cap55.09B
Moderna is involved in mRNA-based therapies, competing in the broader immunotherapy space which overlaps with Neovacs' work on autoimmune diseases.
Novavax
NVAX
Mkt Cap1.53B
Novavax operates in the development of vaccines for infectious diseases, competing indirectly with Neovacs by targeting immune system responses.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation specializes in small molecule drugs for oncology and inflammation, competing in the therapeutic area of immune modulation like Neovacs.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its monoclonal antibodies and inflammatory disease treatments, directly competing with Neovacs in the immunotherapy field.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a leading company in diabetes and biopharmaceuticals, indirectly competing with Neovacs in the broader healthcare and biotech industry.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company focusing on antiviral drugs and other treatments, competing in the immunotherapy and biotech space relevant to Neovacs.

About

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Show more...
CEO
Mr. Hugo Brugiere
Employees
18
Country
France
ISIN
FR0014018EV4
WKN
000A41ZCU

Listings

MU
DE
0LW1.MU
STU
DE
0LW1.STU
LSE
GB
0W8U.LSE
MU
DE
0LW.MU

0 Comments

Share your thoughts

FAQ

What is Neovacs stock price today?▼
The current price of 0LW1.MU is €0.43 EUR — it has decreased by -3.59% in the past 24 hours. Watch Neovacs stock price performance more closely on the chart.
What is Neovacs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Neovacs stocks are traded under the ticker 0LW1.MU.
What is Neovacs market cap?▼
Today Neovacs has the market capitalization of 16.1M
What is Neovacs revenue for the last year?▼
Neovacs revenue for the last year amounts to 541,000 EUR.
What is Neovacs net income for the last year?▼
0LW1.MU net income for the last year is -63.91M EUR.
How many employees does Neovacs have?▼
As of September 07, 2026, the company has 18 employees.
In which sector is Neovacs located?▼
Neovacs operates in the Energy sector.
When did Neovacs complete a stock split?▼
The last stock split for Neovacs was on July 18, 2025 with a ratio of 1:1000.
Where is Neovacs headquartered?▼
Neovacs is headquartered in Paris, France.